| Business Summary | | Elan
Corporation,
plc
is
a
worldwide
pharmaceutical
and
biotechnology
company
focused
on
the
development
and
commercialization
of
products.
Elan
focuses
on
drug
delivery
systems
and
has
expanded
its
therapeutic
focus
through
the
development
and
commercialization
of
new
pharmaceutical
products
for
the
selected
target
markets
of
neurology,
pain
management
and
oncology.
Elan
currently
conducts
its
operations
through
two
primary
business
units:
Elan
Pharmaceuticals
(EP)
and
Elan
Pharmaceutical
Technologies
(EPT).
EP
is
engaged
in
the
discovery,
development
and
marketing
of
therapeutic
products
for
neurological
disorders
and
pain
management,
as
well
as
diagnostic
services
for
neurological
disorders.
EP's
principal
research
and
development
activities
focus
on
Alzheimer's
disease,
pain
management,
epilepsy,
multiple
sclerosis,
Parkinson's
disease,
dystonias
and
other
neurological
disorders.
EPT
is
engaged
in
the
development,
licensing
and
marketing
of
drug
delivery
products
and
technologies. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Elan
is
a
specialty
pharmaceutical
company
focused
on
the
discovery,
development
and
marketing
of
therapeutic
products
and
services
in
neurology,
pain
management
and
oncology.
For
the
six
months
ended
6/30/01,
revenues
rose
26%
to
$890.6
million.
Net
income
before
acct.
change
totalled
$210.7
million,
vs.
a
loss
of
$47
million.
Results
reflect
increased
product
sales
reflecting
the
execution
of
several
new
licenses
and
lower
charges
related
to
merger
costs. | More
from
Market Guide: Significant
Developments |
| | |
| Position | Donal Geaney, 49 | Chairman
and CEO | John Groom, 62 | Pres,
COO | Thomas Lynch, 43 | Vice
Chairman | Shane Cooke | CFO,
Exec. VP, Director | William Clark | Pres,
Elan Pharmaceutical Operations |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|